Current treatment of choice for chronic hepatitis C infection
Clicks: 204
ID: 10298
2011
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
64.4
/100
204 views
163 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Current treatment of choice for chronic hepatitis C infection Tareq Yasin, Thomas R Riley, Ian R SchreibmanPenn State Hershey Medical Center and College of Medicine, Pennsylvania, USAAbstract: More than three million Americans have chronic hepatitis C infection, and the disease remains one of the most common blood-borne infections in the US. Treatment is focused on the chronic form of the disease, because the acute one tends to be self-limiting. In this article, we review the recent literature regarding the most effective therapy against hepatitis C infection, to confirm the current treatment of choice for the disease. We conclude that combination therapy with pegylated interferon and ribavirin remains the initial treatment of choice. New research focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early data that appear to be promising.Keywords: hepatitis C virus, infection, chronic, treatment, pegylated interferon, ribavirinReference Key |
yasin2011currentinfection
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | Tareq Yasin;Thomas R Riley;Ian R Schreibman; |
Journal | Infection and drug resistance |
Year | 2011 |
DOI | 10.2147/IDR.S4827 |
URL | |
Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.